Clicky

Sesen Bio, Inc.(SESN)

Description: Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.


Keywords: Medicine Cancer Solid Tumors Oncology Monoclonal Antibodies Carcinoma Bladder Cancer Checkpoint Inhibitor Fusion Protein Squamous Cell Carcinoma Causes Of Death Therapies For Patients With Cancer

Home Page: sesenbio.com

SESN Technical Analysis

245 First Street
Cambridge, MA 02142
United States
Phone: 617 444 8550


Officers

Name Title
Dr. Thomas R. Cannell D.V.M. Pres, CEO & Director
Ms. Monica Forbes CFO & Treasurer
Dr. Glen C. MacDonald Chief Technology Officer
Dr. Gregory L. Verdine Ph.D. Co-Founder
Ms. Elly Ryu Corp. Controller & Principal Accounting Officer
Ms. Erin Clark VP of Corp. Strategy & Investor Relations
Mr. Mark R. Sullivan Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Mr. Steve Barbera VP of Market Access
Dr. David Brooks Sr. VP of Clinical Devel.
Dr. Dennis Kim M.D., MPH Chief Medical Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 1.9076
Price-to-Book MRQ: 0.6445
Price-to-Sales TTM: 1.7184
IPO Date: 2014-02-06
Fiscal Year End: December
Full Time Employees: 17
Back to stocks